If I could only buy 1 FTSE 100 stock, I’d put 100% of my money into this one

Investing my entire portfolio in a single FTSE 100 stock is a very risky strategy, but if I had to pick one I’d choose the largest company in the index.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Arrow symbol glowing amid black arrow symbols on black background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I don’t plan to rebalance my stock market portfolio into a single FTSE 100 stock. That’s because I prefer to diversify my investments across different companies and sectors, managing my risk exposure in the process.

Nonetheless, not all shares in the UK’s blue-chip benchmark are equal. I believe some Footsie companies have brighter prospects than others. Accordingly, if I had to choose a single stock to invest in from the index, it would be the Anglo-Swedish pharmaceutical giant AstraZeneca (LSE:AZN).

With a market cap of £182bn, it’s the FTSE 100’s biggest company and I already hold some of its shares. But I think this business has plenty of upside potential for further growth. Here’s why.

Stunning returns

First, it’s worth appreciating the spectacular growth in the AstraZeneca share price. Over the past five years, the stock has climbed nearly 118%. If I’d bought back in mid-2018, my initial investment would have more than doubled in value today.

The upward trajectory has been remarkably consistent too, as the chart above shows. No doubt the company was a beneficiary from the pandemic thanks to its Covid-19 vaccine Vaxzevria, but there’s much more to the business. After all, the stock is close to an all-time high today despite the company’s guidance that it will deliver “minimal” sales of Vaxzevria this year.

A premium pipeline

AstraZeneca’s drugs portfolio is impressive. Spanning a range of diseases, some of its star medicines include lung cancer drug Tagrisso, diabetes drug Farxiga, and leukaemia drug Calquence.

The firm currently has 178 projects in its pipeline, including 14 new molecular entities in its late-stage pipeline. A considerable number of its drugs are currently undergoing phase III clinical trials across its key therapy areas. The company expects to launch 15 new medicines by the end of the decade, some of which could produce more than $1bn in annual revenue.

What’s more, AstraZeneca’s financial results continue to impress. In the first quarter it delivered $10.6bn in revenue. That was flat on a constant currency basis, but once the falling Covid-19 medicine sales are removed from the picture, it represents 15% growth.

This is evidence of depth in the company’s strength across its various divisions. It has indicated full-year revenue will grow by a low-to-mid-single-digit figure.


However, all stocks face risks, and AstraZeneca is no exception. At present, it has a price-to-earnings ratio of 46.5, which is a considerably higher multiple than the FTSE 100 average of just below 10. The stock certainly isn’t cheap. Any disappointing results from clinical trials could deal a blow to the share price.

In addition, the firm’s balance sheet isn’t flawless either. AstraZeneca’s debt-to-equity ratio is currently 88%. That’s a little high for my liking and I’d like to see the company make some progress in reducing its net debt position.

Why I own AstraZeneca shares

Although there’s a risk the growth opportunities from its pipeline have been priced in, I still think AstraZeneca is a great long-term hold for me. It’s a highly innovative company and CEO Pascal Soriot has done a stellar job over the past decade.

While I wouldn’t invest everything in a single FTSE 100 stock, if it came to it, I’d choose AstraZeneca.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Charlie Carman has positions in AstraZeneca Plc. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young woman holding up three fingers
Investing Articles

I’d earn £1,260 in passive income by investing a £20k Isa in these 3 ultra-high-yield stocks

I'm on the hunt for passive income and I reckon the following FTSE 100 stocks should help me generate it…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

Could these beleaguered FTSE 100 stocks stage a turnaround?

Could these FTSE 100 stocks be primed for recovery after difficult times? Sumayya Mansoor takes a look at what could…

Read more »

Young black man looking at phone while on the London Overground
Investing Articles

Is this FTSE 100 giant one of the best income stocks out there?

Our writer takes a closer look at this medical business as a potential income stock for her portfolio, even though…

Read more »

Bournemouth at night with a fireworks display from the pier
Investing Articles

£2k in a Stocks and Shares ISA? One top stock I’d buy before the New Year!

Here's one US stock this writer thinks could grow for a long time to come and deliver attractive returns in…

Read more »

Front view photo of a woman using digital tablet in London
Investing Articles

How I’d invest £4k in my SIPP with the aim of doubling my money

Jon Smith talks through how he'd use dividend growth stocks to grow a SIPP pot consistently to achieve strong long-term…

Read more »

Stack of one pound coins falling over
Investing Articles

£3 a day vs £30 a day passive income plan

What’s the difference between a £3 a day and £30 a day passive income plan? More to the point, how…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

Is the British American Tobacco (BAT) share price NOW too cheap to miss?

The BAT share price has sunk again after another chilly market update. But is the company now a brilliant bargain…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

I’m using December to snap up cheap shares!

This Fool is keen to use this month to add some cheap shares to his portfolio. Here he examines one…

Read more »